Apexium Financial’s Gilead Sciences GILD Stock Holding History

Apexium Financial’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,487	Closed	-$201K	–	245
2023 Q4	$201K	Buy	+2,487	New	+$194K	0.01%	260

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Apexium Financial's GILD Position: Q1 2024 in Review

Apexium Financial sold out of Gilead Sciences (GILD) in Q1 2024, closing a stake of 2,487 shares — an estimated $201K sold.

Apexium Financial first reported a position in GILD in Q4 2023 and held it in 1 quarter. The position peaked at $201K in Q4 2023. 1,722 funds tracked by Wall St. Rank hold GILD as of Q1 2024.

Apexium Financial reported no remaining Gilead Sciences position as of Q1 2024 after selling out during the quarter.
Apexium Financial sold 2,487 Gilead Sciences shares in Q1 2024, an estimated $201K.
Apexium Financial first reported a position in Gilead Sciences in Q4 2023 and held it in 1 quarter.
Apexium Financial's Gilead Sciences position peaked at $201K in Q4 2023.
1,722 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.

Based on Apexium Financial's 13F filing for Q1 2024, filed 19 Apr 2024.